Pharmaceuticals, Biotechnology and Life Sciences
After the US president’s Biden said the US Federal government would buy 100 million doses of the COVID-19 vaccine from Moderna and another 100 million from Pfizer, Moderna today confirmed that it is in discussion with the U.S. government to purchase an additional 100 million doses of the Moderna COVID-19 Vaccine for delivery in the third quarter of 2021.
CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry into the tumor microenvironment.
Immunicum AB will move its in-house research and process development activities into a new facility at the Leiden Bio Science…
Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific T-cell engaging antibody for the treatment of metastatic castrate resistant prostate cancer (mCRPC) was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on January 23, 2021.
Myovant Sciences and Pfizer said Monday that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination…
Reuters news agency referred to the Economic Times as saying Monday that Tata Group’s healthcare venture has reportedly started the first discussions with Moderna Inc for a partnership to launch its COVID-19 vaccine in India.
The recently hosted CPhI & P-MEC China 2020 – organized by Informa Markets and CCCMHPIE and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. – attracted a remarkable 46,157 visits of professional pharma visitors, including 5,105 international attendees taking part online.
European Commission’s decision on conditional marketing authorization is expected imminently, after the positive CHMP opinion, which will make BNT162b2 if authorized, the first COVID-19 vaccine available in the European Union.
A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT), as an academia-industry collaboration (investigator Initiated trial) between Apogenix AG and its scientific consultant Henning Walczak and his teams at the University of Cologne and University College London (UCL).
Baris Erdogan, currently Vice President, Site & Patient Networks, at Clinerion, has been promoted by the Board of Directors to the position of Chief Executive Officer as of January 1st, 2021. After a three-year tenure, Clinerion’s current CEO, Ian Rentsch, has decided to step down for personal reasons and to return to his family in Berlin by the end of January, 2021.